Goldman’s Apple Card small business has a surprising subprime dilemma

Goldman’s Apple Card small business has a surprising subprime dilemma


Critical Details
  • Goldman’s reduction level on credit card financial loans is the worst amid large U.S. card issuers and “effectively earlier mentioned subprime lenders” at 2.93%, in accordance to a Sept. 6 take note from JPMorgan.
  • Additional than a quarter of Goldman’s card loans have absent to buyers with FICO scores under 660, in accordance to corporation filings. That could expose the bank to higher losses if the economic system encounters a downturn, as is envisioned by lots of forecasters.
  • CEO David Solomon will possible confront queries from directors about the client organization at a board assembly later this week, according to people with expertise of the matter.



Source

Here are 3 forces that drove the stock market during Wall Street’s comeback week
Finance

Here are 3 forces that drove the stock market during Wall Street’s comeback week

The stock market staged a comeback last week, even as Wall Street waded through a flurry of both upbeat and unsettling headlines. The Nasdaq broke its five-week losing streak on Friday, buoyed by strong advances from our big tech names like Meta Platforms , Nvidia and Amazon . The tech-heavy index ended the week 1.9% […]

Read More
Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’
Finance

Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’

ETF Edge Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’ Published Sat, Feb 21 202611:00 AM EST Blair Bao WATCH LIVE Source

Read More
Stocks making the biggest moves premarket: Grail, Blue Owl Capital, Opendoor Technologies & more
Finance

Stocks making the biggest moves premarket: Grail, Blue Owl Capital, Opendoor Technologies & more

Check out the companies making headlines before the bell. Grail — Shares cratered 47% after the company said a trial of one of its drugs missed its primary endpoint and failed to show statistically significant Stage III-IV cancer reduction. Blue Owl Capital — Shares slid nearly 3%, a day after after the private market and […]

Read More